Literature DB >> 16759169

Chemotherapy for elderly patients with advanced colorectal carcinoma.

Rosa Gallego1, Nuria Sanchez, Joan Maurel.   

Abstract

There is an increasing need to redefine treatment strategies in elderly patients with advanced colorectal carcinoma since they constitute more than 50% of newly diagnosed patients. Taking into account that the vast majority of clinical trials in advanced colorectal carcinoma include patients up to 75 years old, it seems reasonable to consider those patients over 75 years as elderly. In general, 20% of patients have favorable factors (fewer than four liver nodules less than 5 cm in size) and are suitable for local treatments (surgery or local-ablative therapies). Additionally, 40% of patients have poor performance status or are severely disabled owing to geriatric syndromes and/or comorbid diseases (advanced stage) that preclude any treatment strategies. The remainder of patients (fit elderly patients not suitable for radical treatments) constitute the focus of this review.

Entities:  

Mesh:

Year:  2006        PMID: 16759169     DOI: 10.1586/14737140.6.5.795

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  3 in total

1.  Phase II study of first-line chemotherapy with uracil-tegafur plus oral leucovorin in elderly (≥75 years) Japanese patients with metastatic colorectal cancer: SGOSG-CR0501 study.

Authors:  Toshihiko Matsumoto; Tomohiro Nishina; Minoru Mizuta; Akihito Tsuji; Ryouhei Watanabe; Ikuo Takahashi; Yuji Watanabe; Toshikazu Moriwaki; Takashi Maeba; Ichinosuke Hyodo
Journal:  Int J Clin Oncol       Date:  2014-02-20       Impact factor: 3.402

2.  Treatment of patients with metastatic colorectal cancer and poor performance status: current evidence and challenges.

Authors:  Lucila Soares da Silva Rocha; Rachel P Riechelmann
Journal:  Clinics (Sao Paulo)       Date:  2018-09-21       Impact factor: 2.365

3.  Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.

Authors:  Yoshinori Munemoto; Mitsuro Kanda; Keiichiro Ishibashi; Taishi Hata; Michiya Kobayashi; Junichi Hasegawa; Mutsumi Fukunaga; Akinori Takagane; Toshio Otsuji; Yasuhiro Miyake; Michitaka Nagase; Junichi Sakamoto; Masaki Matsuoka; Koji Oba; Hideyuki Mishima
Journal:  BMC Cancer       Date:  2015-10-24       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.